Press Releases

Year

Mar 29, 2021

Wave Life Sciences Provides Update on Phase 1b/2a PRECISION-HD Trials

mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120101 No observed change in wtHTT and NfL during trials Advancing Phase 1b/2a trial for WVE-003 (SNP3) program in HD; WVE-003 uses new PN backbone chemistry modifications, which demonstrate improved

Mar 19, 2021

Wave Life Sciences to Present at the Third Annual Stifel CNS Day

CAMBRIDGE, Mass. , March 19, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno , MD, MBA, President and Chief Executive

Mar 04, 2021

Wave Life Sciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Strong execution in 2020 sets stage for advancing five clinical programs and novel ADAR editing modality in 2021 Data from ongoing PRECISION-HD and OLE clinical trials for Huntington’s disease on track for end of 1Q 2021 Moving towards first patient dosing in three clinical trials with pipeline

Feb 23, 2021

Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021

CAMBRIDGE, Mass. , Feb. 23, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference

Feb 16, 2021

Wave Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass. , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno , MD, MBA, President and Chief Executive

Jan 11, 2021

Wave Life Sciences Highlights Pipeline Progress and Expansion Leveraging New PN Backbone Chemistry Modifications

Three clinical trials to begin in 2021 with compounds containing Wave’s novel PN backbone chemistry modifications Data from ongoing PRECISION-HD and OLE clinical trials for Huntington’s disease expected by end of 1Q 2021 Potential best-in-class ADAR editing platform capability continues to advance,

Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

Downloads

Investor Inquiries

Email Alerts

Press Releases

Press Releases

About

Science

Pipeline

Careers